Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

News release details

Blueprint Medicines to Report First Quarter 2016 Financial Results on Tuesday, May 10, 2016

May 3, 2016 at 8:00 AM EDT

CAMBRIDGE, Mass., May 3, 2016 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today announced that it will report first quarter 2016 financial results on Tuesday, May 10, 2016. Blueprint Medicines' management team will host a live conference call and audio webcast at 8:00 a.m. EDT on Tuesday, May 10, 2016 to discuss the financial results and provide a corporate update.

Blueprint Medicines

To access the conference call, please dial 1-855-728-4793 (domestic) or 1-503-343-6666 (international) and refer to conference ID 92012739. An audio webcast of the call will also be available in the Investors section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.

About Blueprint Medicines

Blueprint Medicines is developing a new generation of highly selective and potent kinase medicines to improve the lives of patients with genomically defined diseases. The Company's approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing three programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma and systemic mastocytosis, as well as multiple programs in research and preclinical development. For more information, please visit www.blueprintmedicines.com.

Logo - http://photos.prnewswire.com/prnh/20150605/221118LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/blueprint-medicines-to-report-first-quarter-2016-financial-results-on-tuesday-may-10-2016-300261517.html

SOURCE Blueprint Medicines Corporation

Investor Relations: Kristin Williams, Blueprint Medicines Corporation, 617-714-6674, kwilliams@blueprintmedicines.com; Media Relations: Dan Quinn, Ten Bridge Communications, Inc., 781-475-7974, dan@tenbridgecommunications.com